Profile - To The Moon

JustinTeo4D

Posts · 8Posts · 8
Following · 0Following · 0
Followers · 0Followers · 0

- JustinTeo4DJustinTeo4D
  ·2021-04-12
  Go get em
  Charlie Munger Prefers Alibaba Stock to Treasury Bills. Here’s Why.
  Warren Buffett’s longtime partner Charlie Munger recently disclosed a new investment in the Chinese
  Charlie Munger Prefers Alibaba Stock to Treasury Bills. Here’s Why.
  341 Comment
  1
  Share
  Report
- JustinTeo4DJustinTeo4D
  ·2021-04-12
  Oh nice man this is sick
  XPeng Inc.: A Reawakening
  Valuation is middling but not overvalued like in the past.Recent announcement of capacity expansion in Wuhan lends better operational and sales visibility.Company could breakeven and finally reach positive profits soon; major improvements seen in operating margins.Feared chip shortage was not a disaster, deliveries are still strong.Government support, China's creation of an EV ecosystem.XPEV's strong deliveries describe not only excellent support from the private sector, but also the Chinese go
  XPeng Inc.: A Reawakening
  434 1
  5
  Share
  Report
- JustinTeo4DJustinTeo4D
  ·2021-04-10
  Wow sick man Coinbase
  Biden Boosts Health, Education in $1.52 Trillion Budget Request
  White House releases outline of budget request for 2022 Congress likely to significantly reshape pla
  Biden Boosts Health, Education in $1.52 Trillion Budget Request
  173 Comment
  2
  Share
  Report
- JustinTeo4DJustinTeo4D
  ·2021-04-10
  Oh no
  Sorry, this post has been deleted
  252 Comment
  1
  Share
  Report
- JustinTeo4DJustinTeo4D
  ·2021-04-09
  Oh I’m Intricked
  299 Comment
  Like
  Share
  Report
- JustinTeo4DJustinTeo4D
  ·2021-03-05
  Ok
  Sorry, this post has been deleted
  239 Comment
  1
  Share
  Report
- JustinTeo4DJustinTeo4D
  ·2021-03-05
  Oh no this is bad
  Baidu said to win Hong Kong bourse nod for second listing
  HONG KONG (BLOOMBERG) - Chinese search engine giant Baidu has secured approval from the Hong Kong st
  Baidu said to win Hong Kong bourse nod for second listing
  230 Comment
  Like
  Share
  Report
- JustinTeo4DJustinTeo4D
  ·2021-03-05
  Oh
  3 Medtech Trends That Will Outlive the Pandemic
  Vaccines are starting to roll out in many parts of the world and some believe the beginning of the e
  3 Medtech Trends That Will Outlive the Pandemic
  331 Comment
  Like
  Share
  Report
No followers yet

Most Discussed

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"isCurrentUser":false,"userPageInfo":{"id":"3578014849238566","uuid":"3578014849238566","gmtCreate":1614921608264,"gmtModify":1617939294776,"name":"JustinTeo4D","pinyin":"justinteo4d","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.tigerbbs.com/a83ccf20d9e0affe93fe9f99854a3894","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":1,"headSize":16,"tweetSize":8,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-2","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Senior Tiger","description":"Join the tiger community for 1000 days","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.12.01","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":2,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":1,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":342879285,"gmtCreate":1618203529747,"gmtModify":1704707469813,"author":{"id":"3578014849238566","authorId":"3578014849238566","name":"JustinTeo4D","avatar":"https://static.tigerbbs.com/a83ccf20d9e0affe93fe9f99854a3894","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3578014849238566","authorIdStr":"3578014849238566"},"themes":[],"htmlText":"Go get em&nbsp;","listText":"Go get em&nbsp;","text":"Go get em","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/342879285","repostId":"1166514197","repostType":4,"repost":{"id":"1166514197","pubTimestamp":1618198292,"share":"https://ttm.financial/m/news/1166514197?lang=&edition=fundamental","pubTime":"2021-04-12 11:31","market":"us","language":"en","title":"Charlie Munger Prefers Alibaba Stock to Treasury Bills. Here’s Why.","url":"https://stock-news.laohu8.com/highlight/detail?id=1166514197","media":"Barrons","summary":"Warren Buffett’s longtime partner Charlie Munger recently disclosed a new investment in the Chinese ","content":"<p>Warren Buffett’s longtime partner Charlie Munger recently disclosed a new investment in the Chinese internet giant Alibaba Group Holding.</p>\n<p>Daily Journal (ticker: DJCO)—Munger has served as chairman since 1977, and provides the firm with investing expertise—disclosed last week in a Securities and Exchange Commission filing that it owned 165,320 Alibaba (BABA) American depositary receipts as of March 31. Daily Journal hadn’t owned any at the end of 2020.</p>\n<p>In response to a request for comment on the investment, Munger, who is also the vice chairman ofBerkshire Hathaway(BRKb), provided a statement to<i>Barron’s</i>:</p>\n<p>“Daily Journal Corporation has and needs securities held as cash equivalents. These cash equivalents would normally be U.S. Treasury Bills. But, with returns on Treasury Bills now so low, the Company instead, invests in common stock. And, unless its long term prospects seem good, a common stock is not considered to be a good cash equivalent.</p>\n<p>“A minor part of Daily Journal Corporation’s cash equivalents now consists of a tiny amount of Alibaba common stock.”</p>\n<p>That “tiny amount” was valued at $37.5 million as of March 31. Daily Journal could have bought the Alibaba ADRs at any point in the first quarter. So far this year, the ADRs are down 4%, while theS&amp;P 500index is up about 9.9%.</p>\n<p>Alibaba ADRs underperformed the market last year, only gaining 9.7% while the index rose 16.3%. The ADRs tumbled in December when an affiliate was forced by Chinese regulators toscuttle an initial public offering. Barron’s has written about a variety of risks ofinvesting in China.</p>\n<p>Daily Journal owns other stocks, as well, and its U.S.-traded investments totaled about $200 million as of March 31. Positions in other investments were unchanged, and the largest investments by dollar value remained&nbsp;Bank of America(BAC) stock at 2.3 million shares, and&nbsp;Wells Fargo(WFC) at 1.6 million shares; Daily Journal’s positions in those two bank stocks are unchanged since at least theend of 2013. The company was required to begin disclosing investment positions at that point because its U.S.-traded portfolio topped the threshold of $100 million.</p>\n<p>Interestingly, Warren Buffett has recently overseen trades in both banks through Berkshire Hathaway’s portfolio. Berkshire Hathaway is Bank of America’s largest investor, with more than 1 billion shares after Buffett went ona buying spree&nbsp;last year. Berkshire Hathaway has also been&nbsp;slashing its investment&nbsp;in Wells Fargo. We estimated that cutting the Wells Fargo position, and that of other bank stocks, cost Berkshire Hathaway&nbsp;about $10 billion&nbsp;as the sector later rallied.</p>\n<p>Also, Berkshire Hathaway doesn’t own any Alibaba ADRs.</p>","source":"lsy1601382232898","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Charlie Munger Prefers Alibaba Stock to Treasury Bills. Here’s Why.</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCharlie Munger Prefers Alibaba Stock to Treasury Bills. Here’s Why.\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-12 11:31 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.barrons.com/articles/berkshire-hathaway-charlie-munger-prefers-alibaba-stock-to-treasury-bills-51617813729?mod=RTA><strong>Barrons</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Warren Buffett’s longtime partner Charlie Munger recently disclosed a new investment in the Chinese internet giant Alibaba Group Holding.\nDaily Journal (ticker: DJCO)—Munger has served as chairman ...</p>\n\n<a href=\"https://www.barrons.com/articles/berkshire-hathaway-charlie-munger-prefers-alibaba-stock-to-treasury-bills-51617813729?mod=RTA\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"09988":"阿里巴巴-W","BABA":"阿里巴巴"},"source_url":"https://www.barrons.com/articles/berkshire-hathaway-charlie-munger-prefers-alibaba-stock-to-treasury-bills-51617813729?mod=RTA","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1166514197","content_text":"Warren Buffett’s longtime partner Charlie Munger recently disclosed a new investment in the Chinese internet giant Alibaba Group Holding.\nDaily Journal (ticker: DJCO)—Munger has served as chairman since 1977, and provides the firm with investing expertise—disclosed last week in a Securities and Exchange Commission filing that it owned 165,320 Alibaba (BABA) American depositary receipts as of March 31. Daily Journal hadn’t owned any at the end of 2020.\nIn response to a request for comment on the investment, Munger, who is also the vice chairman ofBerkshire Hathaway(BRKb), provided a statement toBarron’s:\n“Daily Journal Corporation has and needs securities held as cash equivalents. These cash equivalents would normally be U.S. Treasury Bills. But, with returns on Treasury Bills now so low, the Company instead, invests in common stock. And, unless its long term prospects seem good, a common stock is not considered to be a good cash equivalent.\n“A minor part of Daily Journal Corporation’s cash equivalents now consists of a tiny amount of Alibaba common stock.”\nThat “tiny amount” was valued at $37.5 million as of March 31. Daily Journal could have bought the Alibaba ADRs at any point in the first quarter. So far this year, the ADRs are down 4%, while theS&P 500index is up about 9.9%.\nAlibaba ADRs underperformed the market last year, only gaining 9.7% while the index rose 16.3%. The ADRs tumbled in December when an affiliate was forced by Chinese regulators toscuttle an initial public offering. Barron’s has written about a variety of risks ofinvesting in China.\nDaily Journal owns other stocks, as well, and its U.S.-traded investments totaled about $200 million as of March 31. Positions in other investments were unchanged, and the largest investments by dollar value remained Bank of America(BAC) stock at 2.3 million shares, and Wells Fargo(WFC) at 1.6 million shares; Daily Journal’s positions in those two bank stocks are unchanged since at least theend of 2013. The company was required to begin disclosing investment positions at that point because its U.S.-traded portfolio topped the threshold of $100 million.\nInterestingly, Warren Buffett has recently overseen trades in both banks through Berkshire Hathaway’s portfolio. Berkshire Hathaway is Bank of America’s largest investor, with more than 1 billion shares after Buffett went ona buying spree last year. Berkshire Hathaway has also been slashing its investment in Wells Fargo. We estimated that cutting the Wells Fargo position, and that of other bank stocks, cost Berkshire Hathaway about $10 billion as the sector later rallied.\nAlso, Berkshire Hathaway doesn’t own any Alibaba ADRs.","news_type":1},"isVote":1,"tweetType":1,"viewCount":341,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":342941555,"gmtCreate":1618170450877,"gmtModify":1704707048432,"author":{"id":"3578014849238566","authorId":"3578014849238566","name":"JustinTeo4D","avatar":"https://static.tigerbbs.com/a83ccf20d9e0affe93fe9f99854a3894","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3578014849238566","authorIdStr":"3578014849238566"},"themes":[],"htmlText":"Oh nice man this is sick","listText":"Oh nice man this is sick","text":"Oh nice man this is sick","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/342941555","repostId":"1142324412","repostType":4,"repost":{"id":"1142324412","pubTimestamp":1617982207,"share":"https://ttm.financial/m/news/1142324412?lang=&edition=fundamental","pubTime":"2021-04-09 23:30","market":"us","language":"en","title":"XPeng Inc.: A Reawakening","url":"https://stock-news.laohu8.com/highlight/detail?id=1142324412","media":"seekingalpha","summary":"Valuation is middling but not overvalued like in the past.Recent announcement of capacity expansion in Wuhan lends better operational and sales visibility.Company could breakeven and finally reach positive profits soon; major improvements seen in operating margins.Feared chip shortage  was not a disaster, deliveries are still strong.Government support, China's creation of an EV ecosystem.XPEV's strong deliveries describe not only excellent support from the private sector, but also the Chinese go","content":"<p><b>Summary</b></p>\n<ul>\n <li>Valuation is middling but not overvalued like in the past.</li>\n <li>Recent announcement of capacity expansion in Wuhan lends better operational and sales visibility.</li>\n <li>Company could breakeven and finally reach positive profits soon; major improvements seen in operating margins.</li>\n <li>Feared chip shortage (i.e. supply disruption) was not a disaster, deliveries are still strong.</li>\n</ul>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/4e0f3343d69719839f9b8f1d337c3984\" tg-width=\"1536\" tg-height=\"1024\"><span>Photo by Robert Way/iStock Editorial via Getty Images</span></p>\n<p><b>Introduction</b></p>\n<p>The stock price of&nbsp;XPEV&nbsp;has been converging with the performance of the S&amp;P 500 since March 2021, as compared to its massive outperformance in 4Q2020. This could be view positively or negatively. On the bright side, this suggests that price performance would become more predictable with lower volatility, indicative of a broadening consensus on the fundamental prospects of the company. On the other hand, traders may be disappointed its lack of momentum. Therefore, this is probably a good time to stop viewing XPEV as purely a trade, but re-analyze its merits as a fundamentally-driven investment.</p>\n<p><i>The frenetic performance of XPEV has calmed down in recent weeks, allowing its one year performance to track the S&amp;P 500 more closely</i></p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/9f04001d604ecc7892ef3a76c498578b\" tg-width=\"640\" tg-height=\"236\"><span>Source: SeekingAlpha</span></p>\n<p><i>XPEV's G3 Super Long Range Smart SUV</i></p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/68446a741f9f97afc10f2149c4e13e13\" tg-width=\"640\" tg-height=\"388\"><span>Source: XPeng Motors (G3、P7) Intelligent electric car with Internet DNA</span></p>\n<p><b>Industry and commercial positives</b></p>\n<p>Optimism on EVs and&nbsp;strong industry growth&nbsp;rates are common knowledge by now. The following points suggest specific positives for XPEV that remain intact despite relatively ebbing momentum on the stock's price (as compared to 4Q2020):</p>\n<ol>\n <li><b>Deliveries met despite fears on chip shortage.</b>While the stock's price momentum appears to have ebbed, recent news continues to remain positive. At an industry level, Chinese vehicle manufacturers XPEV andNIOmanaged to manufacture the expected numbers of vehicle deliveries, despite much feared chip shortages.XPEV chalked&nbsp;in record quarterly deliveries of 13,340 EVs in Q1 2021, +487% over the year and +130% over the month in March.NIO delivered&nbsp;20,060 +423% over the year while Q1 deliveries rose 15.6% to 20,060. The challenge these EV manufacturers face now is not so much the ability to deliver on its numbers, but on being able to meet high expectations for the stock price to gain further traction.</li>\n <li><b>Government support, China's creation of an EV ecosystem.</b>XPEV's strong deliveries describe not only excellent support from the private sector, but also the Chinese government's push to develop this part of its industry. XPEV has entered into an agreement with the city of Wuhan to build a factory with a capacity of 100,000 EV units. This is a very significant piece of news, considering its deliveries of just 5,102 in March 2021. Annualizing this number, the new capacity will be more than the whole of XPEV's total historical annual production. This news is interesting and significant since it was just released this week, suggesting it may have yet to be factored into analysts' forecast numbers. This is made more important as XPEV has always been considered a laggard in production capabilities to its larger cousin NIO. General Chinese government support for the EV ecosystem is strong, and the new facility in Wuhan echoes earlier provincial government financial support ($77m) in Guangdong. The reality is, for EVs to gain traction, government willingness to support infrastructure initiatives are highly important (e.g. permits for charging stations, creating incentives to convert from old polluting vehicles to green vehicles, etc.). With China's tradition of central planning, the EV ecosystem is placed on the right footing.</li>\n <li><b>Listing in Hong Kong adds to investor base and liquidity.</b>Going forward,XPEV,NIO, and&nbsp;LI&nbsp;intend tolistin Hong Kong this year. This is a strategic move, and makes the valuation of these companies less susceptible by US political bashing (e.g. the threat of being de-listed) should it occur, since it reflects a wider geographical base. The valuations of these companies may even get a boost given greater global liquidity due to added trading in the Asian time zone.</li>\n</ol>\n<p>Of note, in late March, XPEV held an&nbsp;autonomous driving expedition&nbsp;covering eight cities in China and 3,675 kilometers. The exercise was successful, as minimal human intervention was needed during the expedition and adds another brownie point to XPEV's research and development efforts, placing XPEV on the&nbsp;competitive landscape&nbsp;against rivals such as TSLA and NIO on autonomous driving. Apparently, XPEV's autonomous driving results&nbsp;performed better&nbsp;than TSLA's with fewer human interventions per 100km and better navigation in complex situations.</p>\n<p><b>XPEV's improving financials</b></p>\n<p>Now that we have several quarters of financial data on XPEV, it is worth reviewing how its metrics have been performing. Firstly, market expectations aside, deliveries have been very good as abovementioned, and this is flowing through to revenue numbers. As shown in the below table, growth has been very strong, and revenues are expected to more than double in 2021 and continue to double in 2022. Such growth rates place XPEV at the top end of manufacturing firms, as expected of the fast-growing EV market.</p>\n<p>Another point to note is the improvement in operating margins. As with any \"new tech\" company, initial investments would cause hugely negative operating margins in the beginning. What's important is the company's ability to improve margins and reduce costs over time. In this respect, XPEV has done a good job, with operating margins improving sequentially each quarter. Of note, operating margins started to see major improvements between the Jun-2020 (-142%) and Dec-2020 (-39%) quarters as shown in the table below. Given this trend, the company is likely to breakeven and register positive profits soon, which could be a catalytic re-rating for XPEV. When we pair this analysis with the stock price, it appears that XPEV's recently soft stock price performance is not justified.</p>\n<p>Meanwhile, the balance sheet is expected to remain strong. Equity to total liabilities &amp; equity is 23% as at Dec-2020. As abovementioned, further capital raises with a forthcoming Hong Kong listing will add to XPEV's cash buffer.</p>\n<p><i>XPEV's performance improvement in both revenue and operating margin trends appear to have been ignored by the market due to recent the broad market capitulation</i></p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/f8258dce0cc10e8118a23afce7655bed\" tg-width=\"726\" tg-height=\"737\"><span>*EST = estimate by analysts' consensus from SeekingAlpha</span></p>\n<p><b>XPEV's valuation: somewhere in the middle</b></p>\n<p>XPEV's stock price has done well over the last 6 months versus peers. On a TTM P/S, XPEV is near the middle although its FWD P/S is trading at a premium. However, there could be a general re-rating of the P/S of the sector if the Chinese EV manufacturers reach breakeven in 2021 and record positive profits (our base case belief, given the prevailing trend in XPEV's improving operating margins). This will then allow better price discovery when the companies can then be valued on their P/E ratios.</p>\n<img src=\"https://static.tigerbbs.com/fa975ce545e950a20f809bcc7f698ef6\" tg-width=\"911\" tg-height=\"594\">\n<table>\n <tbody>\n  <tr></tr>\n </tbody>\n</table>\n<p><b>Conclusion and Risks</b></p>\n<p>XPEV's stock price may benefit from two key catalysts: (1) expansion of manufacturing facility in Wuhan, which will concretely raise visibility of revenue growth which is expected to double; (2) a valuation regime change as it progresses from a loss making company to a profitable one, expected by this year. Furthermore, it is worth noting that the valuation is not lofty as compared to price levels in 4Q2020, having fallen over the last couple of months.</p>\n<p>Competition may exist and remain intense, but given the large size of China's market and that there are only a couple of notable players (i.e. NIO, LI), the market remains largely an oligopoly which allows XPEV to retain pricing power.</p>\n<p>Much feared risks of execution in the past appear to have materialized but not in a big way, i.e. the previously expected chip shortage. Given the progression to a post-COVID economy, supply chain links should improve and reduce similar risks in the future.</p>\n<p>On a standalone basis, XPEV's prospects appear bright, and now the key hurdle is whether the NASDAQ will find momentum and exceed previous highs. The base case for this should lean towards the positive as the market is merely in the first year of the economic recovery after the pandemic. Recent price consolidation appears to have created a technical setup for a reawakening of price momentum as consumer activity revives post-pandemic.</p>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>XPeng Inc.: A Reawakening</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nXPeng Inc.: A Reawakening\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-09 23:30 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/article/4418326-xpeng-inc-reawakening><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Summary\n\nValuation is middling but not overvalued like in the past.\nRecent announcement of capacity expansion in Wuhan lends better operational and sales visibility.\nCompany could breakeven and ...</p>\n\n<a href=\"https://seekingalpha.com/article/4418326-xpeng-inc-reawakening\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"XPEV":"小鹏汽车"},"source_url":"https://seekingalpha.com/article/4418326-xpeng-inc-reawakening","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1142324412","content_text":"Summary\n\nValuation is middling but not overvalued like in the past.\nRecent announcement of capacity expansion in Wuhan lends better operational and sales visibility.\nCompany could breakeven and finally reach positive profits soon; major improvements seen in operating margins.\nFeared chip shortage (i.e. supply disruption) was not a disaster, deliveries are still strong.\n\nPhoto by Robert Way/iStock Editorial via Getty Images\nIntroduction\nThe stock price of XPEV has been converging with the performance of the S&P 500 since March 2021, as compared to its massive outperformance in 4Q2020. This could be view positively or negatively. On the bright side, this suggests that price performance would become more predictable with lower volatility, indicative of a broadening consensus on the fundamental prospects of the company. On the other hand, traders may be disappointed its lack of momentum. Therefore, this is probably a good time to stop viewing XPEV as purely a trade, but re-analyze its merits as a fundamentally-driven investment.\nThe frenetic performance of XPEV has calmed down in recent weeks, allowing its one year performance to track the S&P 500 more closely\nSource: SeekingAlpha\nXPEV's G3 Super Long Range Smart SUV\nSource: XPeng Motors (G3、P7) Intelligent electric car with Internet DNA\nIndustry and commercial positives\nOptimism on EVs and strong industry growth rates are common knowledge by now. The following points suggest specific positives for XPEV that remain intact despite relatively ebbing momentum on the stock's price (as compared to 4Q2020):\n\nDeliveries met despite fears on chip shortage.While the stock's price momentum appears to have ebbed, recent news continues to remain positive. At an industry level, Chinese vehicle manufacturers XPEV andNIOmanaged to manufacture the expected numbers of vehicle deliveries, despite much feared chip shortages.XPEV chalked in record quarterly deliveries of 13,340 EVs in Q1 2021, +487% over the year and +130% over the month in March.NIO delivered 20,060 +423% over the year while Q1 deliveries rose 15.6% to 20,060. The challenge these EV manufacturers face now is not so much the ability to deliver on its numbers, but on being able to meet high expectations for the stock price to gain further traction.\nGovernment support, China's creation of an EV ecosystem.XPEV's strong deliveries describe not only excellent support from the private sector, but also the Chinese government's push to develop this part of its industry. XPEV has entered into an agreement with the city of Wuhan to build a factory with a capacity of 100,000 EV units. This is a very significant piece of news, considering its deliveries of just 5,102 in March 2021. Annualizing this number, the new capacity will be more than the whole of XPEV's total historical annual production. This news is interesting and significant since it was just released this week, suggesting it may have yet to be factored into analysts' forecast numbers. This is made more important as XPEV has always been considered a laggard in production capabilities to its larger cousin NIO. General Chinese government support for the EV ecosystem is strong, and the new facility in Wuhan echoes earlier provincial government financial support ($77m) in Guangdong. The reality is, for EVs to gain traction, government willingness to support infrastructure initiatives are highly important (e.g. permits for charging stations, creating incentives to convert from old polluting vehicles to green vehicles, etc.). With China's tradition of central planning, the EV ecosystem is placed on the right footing.\nListing in Hong Kong adds to investor base and liquidity.Going forward,XPEV,NIO, and LI intend tolistin Hong Kong this year. This is a strategic move, and makes the valuation of these companies less susceptible by US political bashing (e.g. the threat of being de-listed) should it occur, since it reflects a wider geographical base. The valuations of these companies may even get a boost given greater global liquidity due to added trading in the Asian time zone.\n\nOf note, in late March, XPEV held an autonomous driving expedition covering eight cities in China and 3,675 kilometers. The exercise was successful, as minimal human intervention was needed during the expedition and adds another brownie point to XPEV's research and development efforts, placing XPEV on the competitive landscape against rivals such as TSLA and NIO on autonomous driving. Apparently, XPEV's autonomous driving results performed better than TSLA's with fewer human interventions per 100km and better navigation in complex situations.\nXPEV's improving financials\nNow that we have several quarters of financial data on XPEV, it is worth reviewing how its metrics have been performing. Firstly, market expectations aside, deliveries have been very good as abovementioned, and this is flowing through to revenue numbers. As shown in the below table, growth has been very strong, and revenues are expected to more than double in 2021 and continue to double in 2022. Such growth rates place XPEV at the top end of manufacturing firms, as expected of the fast-growing EV market.\nAnother point to note is the improvement in operating margins. As with any \"new tech\" company, initial investments would cause hugely negative operating margins in the beginning. What's important is the company's ability to improve margins and reduce costs over time. In this respect, XPEV has done a good job, with operating margins improving sequentially each quarter. Of note, operating margins started to see major improvements between the Jun-2020 (-142%) and Dec-2020 (-39%) quarters as shown in the table below. Given this trend, the company is likely to breakeven and register positive profits soon, which could be a catalytic re-rating for XPEV. When we pair this analysis with the stock price, it appears that XPEV's recently soft stock price performance is not justified.\nMeanwhile, the balance sheet is expected to remain strong. Equity to total liabilities & equity is 23% as at Dec-2020. As abovementioned, further capital raises with a forthcoming Hong Kong listing will add to XPEV's cash buffer.\nXPEV's performance improvement in both revenue and operating margin trends appear to have been ignored by the market due to recent the broad market capitulation\n*EST = estimate by analysts' consensus from SeekingAlpha\nXPEV's valuation: somewhere in the middle\nXPEV's stock price has done well over the last 6 months versus peers. On a TTM P/S, XPEV is near the middle although its FWD P/S is trading at a premium. However, there could be a general re-rating of the P/S of the sector if the Chinese EV manufacturers reach breakeven in 2021 and record positive profits (our base case belief, given the prevailing trend in XPEV's improving operating margins). This will then allow better price discovery when the companies can then be valued on their P/E ratios.\n\n\n\n\n\n\nConclusion and Risks\nXPEV's stock price may benefit from two key catalysts: (1) expansion of manufacturing facility in Wuhan, which will concretely raise visibility of revenue growth which is expected to double; (2) a valuation regime change as it progresses from a loss making company to a profitable one, expected by this year. Furthermore, it is worth noting that the valuation is not lofty as compared to price levels in 4Q2020, having fallen over the last couple of months.\nCompetition may exist and remain intense, but given the large size of China's market and that there are only a couple of notable players (i.e. NIO, LI), the market remains largely an oligopoly which allows XPEV to retain pricing power.\nMuch feared risks of execution in the past appear to have materialized but not in a big way, i.e. the previously expected chip shortage. Given the progression to a post-COVID economy, supply chain links should improve and reduce similar risks in the future.\nOn a standalone basis, XPEV's prospects appear bright, and now the key hurdle is whether the NASDAQ will find momentum and exceed previous highs. The base case for this should lean towards the positive as the market is merely in the first year of the economic recovery after the pandemic. Recent price consolidation appears to have created a technical setup for a reawakening of price momentum as consumer activity revives post-pandemic.","news_type":1},"isVote":1,"tweetType":1,"viewCount":434,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":346337169,"gmtCreate":1617989660951,"gmtModify":1704705754545,"author":{"id":"3578014849238566","authorId":"3578014849238566","name":"JustinTeo4D","avatar":"https://static.tigerbbs.com/a83ccf20d9e0affe93fe9f99854a3894","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3578014849238566","authorIdStr":"3578014849238566"},"themes":[],"htmlText":"Wow sick man Coinbase&nbsp;","listText":"Wow sick man Coinbase&nbsp;","text":"Wow sick man Coinbase","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/346337169","repostId":"1136941144","repostType":4,"repost":{"id":"1136941144","pubTimestamp":1617980884,"share":"https://ttm.financial/m/news/1136941144?lang=&edition=fundamental","pubTime":"2021-04-09 23:08","market":"us","language":"en","title":"Biden Boosts Health, Education in $1.52 Trillion Budget Request","url":"https://stock-news.laohu8.com/highlight/detail?id=1136941144","media":"Bloomberg","summary":"White House releases outline of budget request for 2022\nCongress likely to significantly reshape pla","content":"<ul>\n <li>White House releases outline of budget request for 2022</li>\n <li>Congress likely to significantly reshape plan in coming months</li>\n</ul>\n<p>President Joe Biden proposed major boosts in funding to combat inequality, disease and climate change as part of a $1.52 trillion budget request for 2022, part of his wider push to redefine the role of government in American lives.</p>\n<p>The administration’s outline, released by the White House Friday, kicks off a months-long process in which Congress is likely to significantly reshape the priorities, given stiff Republican opposition to many of the proposals. But the outline showcases how Biden is trying to bend the federal government toward a much greater role in the provision of health care and education.</p>\n<p>Combined with the $1.9 trillion pandemic-relief bill signed last month and a $2.25 trillion infrastructure-and-jobs proposal, the budget marks Biden’s third foray into using the power of the federal government to radically expand help for lower-income and middle-class Americans. A further social-spending package is also coming, all before Biden’s first 100 days have passed.</p>\n<p>Biden on Friday asked for a 15.9% jump in regular non-defense domestic spending for the fiscal year starting in October, with a more than 40% increase in education spending and a 23% jump for health. The overall budget request is an 8.4% boost from the current year, when excluding emergency spending for the pandemic.</p>\n<p>While there’s extra money for Internal Revenue Service enforcement, the plan doesn’t include the tax hikes on individuals that Biden is planning to unveil in coming weeks to help fund his broader expansion in fiscal spending.</p>\n<p><b>‘More Inclusive’</b></p>\n<p>There’s $14 billion extra to address climate change, $20 billion more for high-poverty schools and $6.5 billion for launching a new research agency to develop new treatments and cures for diseases -- along the lines of the Defense Department’s DARPA.</p>\n<p>“This moment of crisis is also a moment of possibility,” acting budget director Shalanda Young said in a message to lawmakers Friday. “Together, America has a chance not simply to go back to the way things were before the Covid-19 pandemic and economic downturn struck, but to begin building a better, stronger, more secure, more inclusive America.”</p>\n<p>The fiscal 2022 budget request comes on top of last week’s proposed eight-year infrastructure-led package, and a forthcoming, longer-term social-spending program expected to total around $1 trillion.</p>\n<p>Unlike those other proposals, the Democrats will need Republican votes in the Senate to pass the annual appropriations bills into which the budget is divided, according to the chamber’s rules. That means getting at least 10 GOP members aboard.</p>\n<p><b>Defense Spending</b></p>\n<p>Republican lawmakers are certain to take issue with many of Biden’s requests.</p>\n<p>The outline has $753 billion for defense programs in the upcoming fiscal year, which represents just a 1.7% increase -- significantly below the 4% to 5% bump advocated by GOP leaders, and a break with recent tradition of keeping defense and non-defense increases on the same scale.</p>\n<p>The White House argued that domestic investments have waned in recent years, and that Biden’s proposed boost on that side of the ledger would simply return the country’s non-defense spending to around the historic norm of 3.3% of gross domestic product.</p>\n<p>Biden includes no money for border-wall construction, canceling unspent funds from previous years, and has asked for $232 million more to study and investigate domestic terrorism in the wake of the insurrection by supporters of former President Donald Trump at the U.S. Capitol.</p>\n<p><b>No Caps</b></p>\n<p>The president’s 2022 request -- which involves just discretionary spending, and not entitlement programs like Medicare, Medicaid and Social Security -- comes without the budget caps that have been in place for a decade. The expiration of those caps, agreed to between the Obama administration and congressional Republicans, has been described by White House officials as an opportunity to pursue investments in areas like education, clean energy and public health.</p>\n<p>“Over the past decade, due in large measure to overly restrictive budget caps, the nation significantly under-invested in core public services, benefits and protections,” Young said.</p>\n<p>And though presidential budgets are routinely ignored on Capitol Hill, administration officials are hopeful the top-line numbers can offer an early guidepost for fellow Democrats who narrowly control both chambers of Congress.</p>\n<p>Priorities identified by the administration include:</p>\n<ul>\n <li>A $3.9 billion increase in funding to battle the opioid epidemic</li>\n <li>$232 million in new money for Department of Justice gun violence prevention programs</li>\n <li>More than $1.2 billion in new spending for aid to Central America, and asylum adjudication amid a surge of migrants at the U.S.-Mexico border.</li>\n</ul>\n<p>Biden is asking Congress to spend $14 billion more on climate programs across the U.S. government, with some $10 billion targeted to clean energy innovation. Much of the funding would go to Energy Department initiatives, including the Advanced Research Projects Agency for Climate, with support for high-risk ventures that offer the potential for changes in the way electricity is generated and used.</p>\n<p>He envisions a $1.4 billion increase for the National Oceanic and Atmospheric Administration, enabling greater work on climate observations and forecasting, and $600 million to buy electric vehicles and equipment for federal agencies such as the U.S. Postal Service, which is in theprocess of turning over its fleet. Another $800 million would go toward making public and assisted housing more energy efficient.</p>\n<p>Biden also calls for an additional $1.2 billion for the Internal Revenue Service to boost oversight of corporations and wealthy taxpayers and improve IRS customer service. It also calls for amulti-year allocation of $417 million to fund audits, which the White House hopes will bring in more revenues from businesses and wealthy taxpayers.</p>\n<p><b>Amtrak Money</b></p>\n<p>The Commerce Department would see a 28% increase --including a doubling of funds for manufacturing-related programs under the National Institute of Standards and Technology. Amtrak -- long favored by Biden -- receives a 35% increase.</p>\n<p>Biden’s budget proposal arrives months later than the usual timeline, and it lacks many of the details -- including plans for raising revenues, economic assumptions and a 10-year outlook -- that ordinarily accompany funding requests.</p>\n<p>Appropriations for 2022 need to be enacted before Oct. 1 to avert a government shutdown.</p>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Biden Boosts Health, Education in $1.52 Trillion Budget Request</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiden Boosts Health, Education in $1.52 Trillion Budget Request\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-09 23:08 GMT+8&nbsp;&nbsp;&nbsp;<a href=http://bloomberg.com/news/articles/2021-04-09/biden-boosts-health-education-in-1-52-trillion-budget-request><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>White House releases outline of budget request for 2022\nCongress likely to significantly reshape plan in coming months\n\nPresident Joe Biden proposed major boosts in funding to combat inequality, ...</p>\n\n<a href=\"http://bloomberg.com/news/articles/2021-04-09/biden-boosts-health-education-in-1-52-trillion-budget-request\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".IXIC":"NASDAQ Composite",".SPX":"S&P 500 Index",".DJI":"道琼斯"},"source_url":"http://bloomberg.com/news/articles/2021-04-09/biden-boosts-health-education-in-1-52-trillion-budget-request","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1136941144","content_text":"White House releases outline of budget request for 2022\nCongress likely to significantly reshape plan in coming months\n\nPresident Joe Biden proposed major boosts in funding to combat inequality, disease and climate change as part of a $1.52 trillion budget request for 2022, part of his wider push to redefine the role of government in American lives.\nThe administration’s outline, released by the White House Friday, kicks off a months-long process in which Congress is likely to significantly reshape the priorities, given stiff Republican opposition to many of the proposals. But the outline showcases how Biden is trying to bend the federal government toward a much greater role in the provision of health care and education.\nCombined with the $1.9 trillion pandemic-relief bill signed last month and a $2.25 trillion infrastructure-and-jobs proposal, the budget marks Biden’s third foray into using the power of the federal government to radically expand help for lower-income and middle-class Americans. A further social-spending package is also coming, all before Biden’s first 100 days have passed.\nBiden on Friday asked for a 15.9% jump in regular non-defense domestic spending for the fiscal year starting in October, with a more than 40% increase in education spending and a 23% jump for health. The overall budget request is an 8.4% boost from the current year, when excluding emergency spending for the pandemic.\nWhile there’s extra money for Internal Revenue Service enforcement, the plan doesn’t include the tax hikes on individuals that Biden is planning to unveil in coming weeks to help fund his broader expansion in fiscal spending.\n‘More Inclusive’\nThere’s $14 billion extra to address climate change, $20 billion more for high-poverty schools and $6.5 billion for launching a new research agency to develop new treatments and cures for diseases -- along the lines of the Defense Department’s DARPA.\n“This moment of crisis is also a moment of possibility,” acting budget director Shalanda Young said in a message to lawmakers Friday. “Together, America has a chance not simply to go back to the way things were before the Covid-19 pandemic and economic downturn struck, but to begin building a better, stronger, more secure, more inclusive America.”\nThe fiscal 2022 budget request comes on top of last week’s proposed eight-year infrastructure-led package, and a forthcoming, longer-term social-spending program expected to total around $1 trillion.\nUnlike those other proposals, the Democrats will need Republican votes in the Senate to pass the annual appropriations bills into which the budget is divided, according to the chamber’s rules. That means getting at least 10 GOP members aboard.\nDefense Spending\nRepublican lawmakers are certain to take issue with many of Biden’s requests.\nThe outline has $753 billion for defense programs in the upcoming fiscal year, which represents just a 1.7% increase -- significantly below the 4% to 5% bump advocated by GOP leaders, and a break with recent tradition of keeping defense and non-defense increases on the same scale.\nThe White House argued that domestic investments have waned in recent years, and that Biden’s proposed boost on that side of the ledger would simply return the country’s non-defense spending to around the historic norm of 3.3% of gross domestic product.\nBiden includes no money for border-wall construction, canceling unspent funds from previous years, and has asked for $232 million more to study and investigate domestic terrorism in the wake of the insurrection by supporters of former President Donald Trump at the U.S. Capitol.\nNo Caps\nThe president’s 2022 request -- which involves just discretionary spending, and not entitlement programs like Medicare, Medicaid and Social Security -- comes without the budget caps that have been in place for a decade. The expiration of those caps, agreed to between the Obama administration and congressional Republicans, has been described by White House officials as an opportunity to pursue investments in areas like education, clean energy and public health.\n“Over the past decade, due in large measure to overly restrictive budget caps, the nation significantly under-invested in core public services, benefits and protections,” Young said.\nAnd though presidential budgets are routinely ignored on Capitol Hill, administration officials are hopeful the top-line numbers can offer an early guidepost for fellow Democrats who narrowly control both chambers of Congress.\nPriorities identified by the administration include:\n\nA $3.9 billion increase in funding to battle the opioid epidemic\n$232 million in new money for Department of Justice gun violence prevention programs\nMore than $1.2 billion in new spending for aid to Central America, and asylum adjudication amid a surge of migrants at the U.S.-Mexico border.\n\nBiden is asking Congress to spend $14 billion more on climate programs across the U.S. government, with some $10 billion targeted to clean energy innovation. Much of the funding would go to Energy Department initiatives, including the Advanced Research Projects Agency for Climate, with support for high-risk ventures that offer the potential for changes in the way electricity is generated and used.\nHe envisions a $1.4 billion increase for the National Oceanic and Atmospheric Administration, enabling greater work on climate observations and forecasting, and $600 million to buy electric vehicles and equipment for federal agencies such as the U.S. Postal Service, which is in theprocess of turning over its fleet. Another $800 million would go toward making public and assisted housing more energy efficient.\nBiden also calls for an additional $1.2 billion for the Internal Revenue Service to boost oversight of corporations and wealthy taxpayers and improve IRS customer service. It also calls for amulti-year allocation of $417 million to fund audits, which the White House hopes will bring in more revenues from businesses and wealthy taxpayers.\nAmtrak Money\nThe Commerce Department would see a 28% increase --including a doubling of funds for manufacturing-related programs under the National Institute of Standards and Technology. Amtrak -- long favored by Biden -- receives a 35% increase.\nBiden’s budget proposal arrives months later than the usual timeline, and it lacks many of the details -- including plans for raising revenues, economic assumptions and a 10-year outlook -- that ordinarily accompany funding requests.\nAppropriations for 2022 need to be enacted before Oct. 1 to avert a government shutdown.","news_type":1},"isVote":1,"tweetType":1,"viewCount":173,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":346337016,"gmtCreate":1617989634635,"gmtModify":1704705754383,"author":{"id":"3578014849238566","authorId":"3578014849238566","name":"JustinTeo4D","avatar":"https://static.tigerbbs.com/a83ccf20d9e0affe93fe9f99854a3894","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3578014849238566","authorIdStr":"3578014849238566"},"themes":[],"htmlText":"Oh no&nbsp;","listText":"Oh no&nbsp;","text":"Oh no","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/346337016","repostId":"1104081344","repostType":4,"isVote":1,"tweetType":1,"viewCount":252,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":348536696,"gmtCreate":1617939084515,"gmtModify":1704705072250,"author":{"id":"3578014849238566","authorId":"3578014849238566","name":"JustinTeo4D","avatar":"https://static.tigerbbs.com/a83ccf20d9e0affe93fe9f99854a3894","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3578014849238566","authorIdStr":"3578014849238566"},"themes":[],"htmlText":"Oh I’m Intricked&nbsp;","listText":"Oh I’m Intricked&nbsp;","text":"Oh I’m Intricked","images":[{"img":"https://static.tigerbbs.com/fd9f4d3c0e5267f70bb42c516d41282e","width":"1125","height":"2632"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/348536696","isVote":1,"tweetType":1,"viewCount":299,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":367160419,"gmtCreate":1614921985831,"gmtModify":1704777019109,"author":{"id":"3578014849238566","authorId":"3578014849238566","name":"JustinTeo4D","avatar":"https://static.tigerbbs.com/a83ccf20d9e0affe93fe9f99854a3894","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3578014849238566","authorIdStr":"3578014849238566"},"themes":[],"htmlText":"Ok&nbsp;","listText":"Ok&nbsp;","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/367160419","repostId":"2117500955","repostType":4,"isVote":1,"tweetType":1,"viewCount":239,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":367160545,"gmtCreate":1614921973287,"gmtModify":1704777018948,"author":{"id":"3578014849238566","authorId":"3578014849238566","name":"JustinTeo4D","avatar":"https://static.tigerbbs.com/a83ccf20d9e0affe93fe9f99854a3894","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3578014849238566","authorIdStr":"3578014849238566"},"themes":[],"htmlText":"Oh no this is bad","listText":"Oh no this is bad","text":"Oh no this is bad","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/367160545","repostId":"2117500955","repostType":4,"repost":{"id":"2117500955","pubTimestamp":1614906377,"share":"https://ttm.financial/m/news/2117500955?lang=&edition=fundamental","pubTime":"2021-03-05 09:06","market":"us","language":"en","title":"Baidu said to win Hong Kong bourse nod for second listing","url":"https://stock-news.laohu8.com/highlight/detail?id=2117500955","media":"The Straits Times","summary":"HONG KONG (BLOOMBERG) - Chinese search engine giant Baidu has secured approval from the Hong Kong st","content":"<div>\n<p>HONG KONG (BLOOMBERG) - Chinese search engine giant Baidu has secured approval from the Hong Kong stock exchange for a second listing in the city, according to people familiar with the matter.\nNasdaq-...</p>\n\n<a href=\"http://www.straitstimes.com/business/companies-markets/baidu-said-to-win-hong-kong-bourse-nod-for-second-listing\">Web Link</a>\n\n</div>\n","source":"straits_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Baidu said to win Hong Kong bourse nod for second listing</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBaidu said to win Hong Kong bourse nod for second listing\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-03-05 09:06 GMT+8&nbsp;&nbsp;&nbsp;<a href=http://www.straitstimes.com/business/companies-markets/baidu-said-to-win-hong-kong-bourse-nod-for-second-listing><strong>The Straits Times</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>HONG KONG (BLOOMBERG) - Chinese search engine giant Baidu has secured approval from the Hong Kong stock exchange for a second listing in the city, according to people familiar with the matter.\nNasdaq-...</p>\n\n<a href=\"http://www.straitstimes.com/business/companies-markets/baidu-said-to-win-hong-kong-bourse-nod-for-second-listing\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BIDU":"百度","QNETCN":"纳斯达克中美互联网老虎指数"},"source_url":"http://www.straitstimes.com/business/companies-markets/baidu-said-to-win-hong-kong-bourse-nod-for-second-listing","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2117500955","content_text":"HONG KONG (BLOOMBERG) - Chinese search engine giant Baidu has secured approval from the Hong Kong stock exchange for a second listing in the city, according to people familiar with the matter.\nNasdaq-listed Baidu plans to launch its share sale as soon as next week, the people said, asking not to be identified as the information is private. The offering could raise at least US$3.5 billion (S$4.68 billion), Bloomberg News has reported.\nA representative for the company declined to comment. Shares in Baidu fell 6.2 per cent in the US on Thursday (March 4) amid a selloff in technology stocks.\nBaidu follows online car-sales website Autohome in seeking a trading foothold in the Asian financial hub this year, after a wave of such share sales in 2020 which saw some US$17 billion raised. Other companies looking at selling shares in the city include Tencent Music Entertainment Group and video company Bilibili.\nA wave of US-listed Chinese firms have been listing in Hong Kong since Alibaba Group Holding kicked off the trend in late 2019. Deteriorating relations between the world's two biggest economies have risked threatening Chinese companies' access to America's capital markets. The second listings also enable the companies to expand their investor bases closer to their home markets.\nOnce one of China's big three tech leaders alongside Alibaba and Tencent Holdings, Baidu is now playing catch-up as the country's internet users increasingly shift from desktop to mobile. It began years ago to sink billions of dollars into areas from language learning to voice interaction and autonomous driving, betting on smart devices and vehicles of the future. But that endeavour ran into trouble in the initial stages, capped by the departures of several pivotal executives.\nNow, aided by steady investment in R&D and Beijing's focus on developing smart nationwide infrastructure, commercialization cases are finally coming to the fore: in January, the company announced it's teaming up with Zhejiang Geely Holding Group to produce smart electric vehicles. The tie-up is intended to help Baidu deploy its Apollo self-driving tech in more vehicles, a person familiar with the matter has said.","news_type":1},"isVote":1,"tweetType":1,"viewCount":230,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":367187480,"gmtCreate":1614921852740,"gmtModify":1704777017486,"author":{"id":"3578014849238566","authorId":"3578014849238566","name":"JustinTeo4D","avatar":"https://static.tigerbbs.com/a83ccf20d9e0affe93fe9f99854a3894","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3578014849238566","authorIdStr":"3578014849238566"},"themes":[],"htmlText":"Oh&nbsp;","listText":"Oh&nbsp;","text":"Oh","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/367187480","repostId":"1138978257","repostType":4,"repost":{"id":"1138978257","pubTimestamp":1614913165,"share":"https://ttm.financial/m/news/1138978257?lang=&edition=fundamental","pubTime":"2021-03-05 10:59","market":"us","language":"en","title":"3 Medtech Trends That Will Outlive the Pandemic","url":"https://stock-news.laohu8.com/highlight/detail?id=1138978257","media":"Nasdaq","summary":"Vaccines are starting to roll out in many parts of the world and some believe the beginning of the e","content":"<p>Vaccines are starting to roll out in many parts of the world and some believe the beginning of the end of the pandemic is in sight. Optimism is always welcome, but it’s important to acknowledge the challenges aren’t all behind us.</p>\n<p>Neither are the solutions to those challenges.</p>\n<p>Innovative and exciting medtech solutions emerged over the past year in attempts to address our pandemic-induced problems head on, particularly in the field of medical technology. Which of these technologies offer advantages that go beyond the inconveniences of social distancing, and provide permanent value once relative normality has returned?</p>\n<p><b>Patient Safety</b></p>\n<p>While increased awareness of patient safety has made major strides in the last decade, COVID-19 has thrown the issue into the spotlight. It was 2016 when BMJ published a&nbsp;report&nbsp;citing medical errors as the third leading cause of death in the United States behind heart disease and cancer. The medical community took a brief moment to pause and reflect on how a certain proportion of human loss, through human error, is something we as a society have traditionally accepted. Now, we’re reflecting on patient safety again.</p>\n<p>Social distancing, viral prevention, sanitation, and refined approaches to ICU patients all came to the fore during the height of the pandemic. Malnourishment among ICU patients, for instance, was a much more obscure concern before the pandemic. But with a rising number of patients requiring ICU support alongside more studies highlighting the dangers of malnourishment, medtech providers have developed unique methods to circumvent these dangers.</p>\n<p>Medical communities have even cultivated awareness campaigns to streamline the issue, with projects like the&nbsp;Patient Safety Movement, which aims to raise public awareness, expand clinical support, and create a wider sense of urgency surrounding the issue. The movement works to create and freely share actionable solutions (Actionable Patient Safety Solutions) to help mitigate potential dangers.</p>\n<p>Publications such as the&nbsp;British Medical Journal&nbsp;had already red-flagged it as a serious concern long before the pandemic entered the frame. As such, the issue is unlikely to peter out once we’ve arrived at a point of greater normality.</p>\n<p><b>Telemedicine</b></p>\n<p>Telemedicine is the very epitome of technology-driven healthcare and serves as a literal lifeline for millions of people who do not have access to proper medical facilities.</p>\n<p>In April of 2020, 43.5 percent of Medicare primary care visits&nbsp;utilized&nbsp;telehealth methods rather than in-person visits. One of the major benefits of telehealth over in-person alternatives is that it has reduced contact between patients, healthcare workers, and other patients—making it a fitting solution within social distancing guidelines. Wearable devices enable healthcare workers to have real-time information on patient data while they remain at home, such as physicians being updated remotely by people with diabetes regarding insulin dosages.</p>\n<p>Telemedicine will likely become part of the medtech furniture beyond the pandemic, since its benefits and usability achieved vindication through the necessity of circumstance.</p>\n<p>According&nbsp;to Mordor Intelligence, the industry will be worth more than $66 billion by 2021. It should be stressed that Telemedicine is not a product of 2020. It was being developed much prior and just like patient safety, the pandemic has acted as a wonderful springboard. In essence, telemedicine allows greater access to medical specialists while allowing medicine to treat more patients on a whole. Pandemic or no pandemic, this is a destination medicine will always strive for.</p>\n<p><b>Deep Tech</b></p>\n<p>Digital technology is undeniably altering the way care is both accessed and delivered. 2020 has been a catalyst for this sphere—necessity is the mother of invention, and there has been plenty of necessary demand as of late.</p>\n<p>Deeptech is the generic term designated for technologies not focused on end-user services that includes artificial intelligence, robotics, blockchain, and advanced material science, as well as photonics and electronics, biotech and quantum computing. Deeptech exists as a disruptor with a difference. We think about it as the technology that allows us to transcend the status quo, since current technologies ultimately block progress and deeptech is acting as the un-blocker.</p>\n<p>Swati Chaturvedi, CEO of Propel, put it succinctly in an&nbsp;interview&nbsp;with Medtech Innovation:</p>\n<p>“They are trying to solve big issues that really affect the world around them.. For example, a new medical device or technique fighting cancer.”</p>\n<p>Deep Tech has been taken by the travails of COVID-19, since the effects of the virus represent the most pressing priority for medtech going into the new year. But it would be a mistake to view Deep Tech as some temporary trend, it represents the first step for medtech in one of the most comprehensive transitions of our technological and functional capacities.</p>\n<p>It would be easy to explain away medtech’s activity in 2020 as a direct result of Covid, with trends arising to to address the challenges. The truth is a large proportion of the trends we are seeing now have been in the pipelines for some time, some for decades. In some cases, it's taken extraordinary global circumstances for medical trends to propel, but now that the global mindset is becoming digitized, more demanding, and wearier of potential disaster, such trends are unlikely to depart any time soon. People are anesthetized by familiarity, and it requires a year of extreme trepidation for our mindsets to embrace unconventionally effective solutions.</p>\n<p><i>About Author</i></p>\n<p><i>Doron Besser, Chief Executive Officer: Doron Besser is the CEO of&nbsp;ENvizion Medical&nbsp;and Managing General Partner of Swing Medical. Prior to co-founding ENvizion with Shay Tsuker in 2013, Doron served as President and CEO of Angioslide Ltd., a company specializing in innovative, cost effective angioplasty products. Doron guided the company through its infancy stages, which included complicated animal and human trials, to FDA clearance, CE approval and initial market penetration in Europe and the US. Doron also served as VP of Clinical and Marketing and VP of Business Development at SuperDimension, a leader in minimally-invasive pulmonology devices. Doron holds a Doctor of Medicine from Ludwig Maximillians University in Munich, Germany.</i></p>\n<p>The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.</p>","source":"lsy1603171495471","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Medtech Trends That Will Outlive the Pandemic</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Medtech Trends That Will Outlive the Pandemic\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-03-05 10:59 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.nasdaq.com/articles/3-medtech-trends-that-will-outlive-the-pandemic-2021-03-04><strong>Nasdaq</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Vaccines are starting to roll out in many parts of the world and some believe the beginning of the end of the pandemic is in sight. Optimism is always welcome, but it’s important to acknowledge the ...</p>\n\n<a href=\"https://www.nasdaq.com/articles/3-medtech-trends-that-will-outlive-the-pandemic-2021-03-04\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.nasdaq.com/articles/3-medtech-trends-that-will-outlive-the-pandemic-2021-03-04","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1138978257","content_text":"Vaccines are starting to roll out in many parts of the world and some believe the beginning of the end of the pandemic is in sight. Optimism is always welcome, but it’s important to acknowledge the challenges aren’t all behind us.\nNeither are the solutions to those challenges.\nInnovative and exciting medtech solutions emerged over the past year in attempts to address our pandemic-induced problems head on, particularly in the field of medical technology. Which of these technologies offer advantages that go beyond the inconveniences of social distancing, and provide permanent value once relative normality has returned?\nPatient Safety\nWhile increased awareness of patient safety has made major strides in the last decade, COVID-19 has thrown the issue into the spotlight. It was 2016 when BMJ published a report citing medical errors as the third leading cause of death in the United States behind heart disease and cancer. The medical community took a brief moment to pause and reflect on how a certain proportion of human loss, through human error, is something we as a society have traditionally accepted. Now, we’re reflecting on patient safety again.\nSocial distancing, viral prevention, sanitation, and refined approaches to ICU patients all came to the fore during the height of the pandemic. Malnourishment among ICU patients, for instance, was a much more obscure concern before the pandemic. But with a rising number of patients requiring ICU support alongside more studies highlighting the dangers of malnourishment, medtech providers have developed unique methods to circumvent these dangers.\nMedical communities have even cultivated awareness campaigns to streamline the issue, with projects like the Patient Safety Movement, which aims to raise public awareness, expand clinical support, and create a wider sense of urgency surrounding the issue. The movement works to create and freely share actionable solutions (Actionable Patient Safety Solutions) to help mitigate potential dangers.\nPublications such as the British Medical Journal had already red-flagged it as a serious concern long before the pandemic entered the frame. As such, the issue is unlikely to peter out once we’ve arrived at a point of greater normality.\nTelemedicine\nTelemedicine is the very epitome of technology-driven healthcare and serves as a literal lifeline for millions of people who do not have access to proper medical facilities.\nIn April of 2020, 43.5 percent of Medicare primary care visits utilized telehealth methods rather than in-person visits. One of the major benefits of telehealth over in-person alternatives is that it has reduced contact between patients, healthcare workers, and other patients—making it a fitting solution within social distancing guidelines. Wearable devices enable healthcare workers to have real-time information on patient data while they remain at home, such as physicians being updated remotely by people with diabetes regarding insulin dosages.\nTelemedicine will likely become part of the medtech furniture beyond the pandemic, since its benefits and usability achieved vindication through the necessity of circumstance.\nAccording to Mordor Intelligence, the industry will be worth more than $66 billion by 2021. It should be stressed that Telemedicine is not a product of 2020. It was being developed much prior and just like patient safety, the pandemic has acted as a wonderful springboard. In essence, telemedicine allows greater access to medical specialists while allowing medicine to treat more patients on a whole. Pandemic or no pandemic, this is a destination medicine will always strive for.\nDeep Tech\nDigital technology is undeniably altering the way care is both accessed and delivered. 2020 has been a catalyst for this sphere—necessity is the mother of invention, and there has been plenty of necessary demand as of late.\nDeeptech is the generic term designated for technologies not focused on end-user services that includes artificial intelligence, robotics, blockchain, and advanced material science, as well as photonics and electronics, biotech and quantum computing. Deeptech exists as a disruptor with a difference. We think about it as the technology that allows us to transcend the status quo, since current technologies ultimately block progress and deeptech is acting as the un-blocker.\nSwati Chaturvedi, CEO of Propel, put it succinctly in an interview with Medtech Innovation:\n“They are trying to solve big issues that really affect the world around them.. For example, a new medical device or technique fighting cancer.”\nDeep Tech has been taken by the travails of COVID-19, since the effects of the virus represent the most pressing priority for medtech going into the new year. But it would be a mistake to view Deep Tech as some temporary trend, it represents the first step for medtech in one of the most comprehensive transitions of our technological and functional capacities.\nIt would be easy to explain away medtech’s activity in 2020 as a direct result of Covid, with trends arising to to address the challenges. The truth is a large proportion of the trends we are seeing now have been in the pipelines for some time, some for decades. In some cases, it's taken extraordinary global circumstances for medical trends to propel, but now that the global mindset is becoming digitized, more demanding, and wearier of potential disaster, such trends are unlikely to depart any time soon. People are anesthetized by familiarity, and it requires a year of extreme trepidation for our mindsets to embrace unconventionally effective solutions.\nAbout Author\nDoron Besser, Chief Executive Officer: Doron Besser is the CEO of ENvizion Medical and Managing General Partner of Swing Medical. Prior to co-founding ENvizion with Shay Tsuker in 2013, Doron served as President and CEO of Angioslide Ltd., a company specializing in innovative, cost effective angioplasty products. Doron guided the company through its infancy stages, which included complicated animal and human trials, to FDA clearance, CE approval and initial market penetration in Europe and the US. Doron also served as VP of Clinical and Marketing and VP of Business Development at SuperDimension, a leader in minimally-invasive pulmonology devices. Doron holds a Doctor of Medicine from Ludwig Maximillians University in Munich, Germany.\nThe views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.","news_type":1},"isVote":1,"tweetType":1,"viewCount":331,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"defaultTab":"followers","isTTM":true}